뇌졸중 이차예방을 위한 항혈소판제의 사용: 2012년 한국 뇌졸중 이차예방 진료지침 부분 개정
Antiplatelet Therapy for Secondary Stroke Prevention: 2012 Focused Update of Korean Clinical Practice Guidelines for Stroke
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Writing Committee of Korean clinical practice guidelines for secondary prevention of stroke has reviewed recent randomized controlled trials of cilostazol published after the fi rst edition of Korean clinical practice guidelines that considered evidences published before June 2007. Two clinical trials and 1 meta-analysis which compared cilostazol directly with aspirin in the prevention of stroke in patients with cerebral infarction or transient ischemic attack (TIA) were identifi ed and included for the current guideline update. Review of fi ndings indicates that cilostazol as compared to aspirin achieved a greater reduction of stroke as well as composite vascular events of stroke, myocardial infarction, and vascular death. For safety, cilostazol was associated with fewer major bleeding events than aspirin. Accordingly, new recommendations for cilostazol are made for prevention of stroke in the setting of noncardioembolic stroke or TIA. Changes in the guidelines necessitated by new evidences will be continuously refl ected in future guidelines.
Abstract
Writing Committee of Korean clinical practice guidelines for secondary prevention of stroke has reviewed recent randomized controlled trials of cilostazol published after the fi rst edition of Korean clinical practice guidelines that considered evidences published before June 2007. Two clinical trials and 1 meta-analysis which compared cilostazol directly with aspirin in the prevention of stroke in patients with cerebral infarction or transient ischemic attack (TIA) were identifi ed and included for the current guideline update. Review of fi ndings indicates that cilostazol as compared to aspirin achieved a greater reduction of stroke as well as composite vascular events of stroke, myocardial infarction, and vascular death. For safety, cilostazol was associated with fewer major bleeding events than aspirin. Accordingly, new recommendations for cilostazol are made for prevention of stroke in the setting of noncardioembolic stroke or TIA. Changes in the guidelines necessitated by new evidences will be continuously refl ected in future guidelines.
참고문헌 (14)
- Antithrombotic Trialists’ collaboration, "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", BMJ, 324, pp.71~86 (2002)
- Algra A, "Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin", J Neurol Neurosurg Psychiatry, 66, pp.255~ (1999)
- The writing group of clinical practice guideline for stroke, "Clinical Practice Guideline for Stroke. 1st ed" (2009), Clinical Research Center for Stroke
- 권형민, "2009년 한국 뇌졸중 진료지침에서 이차예방을 위한 항혈소판제 사용에 관한 내용의 부분 개정", 대한뇌졸중학회지, 12(1), pp.1~6 (2010), 대한뇌졸중학회
- Shinohara Y, "Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial", Lancet Neuro, 9, pp.959~968 (2010)
- Kamal AK, "Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin", Cochrane Database Syst Rev (2011)
- Sudo T, "Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity", Biochem Pharmacol, 59, pp.347~356 (2000)
- Iida H, "Comparative effects of cilostazol and aspirin on the impairment of endotheliumdependent cerebral vasodilation caused by acute cigarette smoking in rats", J Thromb Thrombolysis, 29, pp.483~488 (2010)
- Gotoh F, "Cilostazol stroke prevention study: A placebo-controlled double blind trial for secondary prevention of cerebral infarction", Stroke Cerebrovasc Dis, 9, pp.147~157 (2000)
- Huang Y, "Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, doubleblind, pilot study", Lancet Neurol, 7, pp.494~499 (2008)
- Furie KL, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the american heart association", american stroke association, 2010, pp.42, 227~276
- European Stroke Organisation (ESO) executive committee, "ESO writing committe. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008", Cerebrovasc Dis, 25, pp.457~507 (2008)
- Matias-Guiu J, "Comparison of trifl usal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP study: A randomized, double-blind, multicenter trial", Stroke, 34, pp.840~848 (2003)
- Culebras A, "Trifl usal vs aspirin for prevention of cerebral infarction: A randomized stroke study", Neurology, 62, pp.1073~1080 (2004)